AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00301951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study NCT00301951 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00301951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Study NCT00301951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00301951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Study NCT00301951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study NCT00301951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Study NCT00916266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Transplantations with autologous bone marrow mononuclear stem cells by selective posterior cerebral artery angiography
Study NCT02955615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILT-101
Description: Induction phase followed by weekly administrations of ILT-101 on top of SLE background therapy.~SLE background therapy includes ...
Study NCT02955615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Induction phase followed by weekly administrations of placebo on top of SLE background therapy.~SLE background therapy includes ...
Study NCT00650702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost-PPDS
Description: Control of IOP compared to baseline for the low dose of Latanoprost-PPDS for 4 months or until loss of efficacy
Study NCT00650702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost-PPDS
Description: Control of IOP compared to baseline for the medium dose of Latanoprost-PPDS for 4 months or until loss of efficacy
Study NCT00650702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost-PPDS
Description: Control of IOP compared to baseline for the high dose of Latanoprost-PPDS for 4 months or until loss of efficacy
Study NCT01616407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-Methylenedioxymethamphetamine
Description: 75 mg per os, single dose
Study NCT01616407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 40 mg per os, single dose
Study NCT01616407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: capsules identical to MDMA or methylphenidate but containing no active drug
Study NCT01437397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide/Formoterol Fumarate
Description: Inhaled Aclidinium/formoterol FDC 400/12μg, twice per day
Study NCT01437397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide/Formoterol Fumarate
Description: Inhaled Aclidinium/formoterol FDC 400/6μg, twice per day
Study NCT01437397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclidinium Bromide
Description: Inhaled Aclidinium 400 μg, twice per day
Study NCT01437397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Inhaled Formoterol 12 μg, twice per day
Study NCT01437397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled dose-matched placebo, twice per day
Study NCT00798993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured Exercise program
Description: 30 minutes on an exercise bicycle during every dialysis
Study NCT00798993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (25-Hydroxyvitamin D)
Description: Cholecalciferol 2000U per day will be given for duration of study to all participants
Study NCT00798993 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual exercise
Description: Participants randomised to this arm at 3 months will continue on their usual exercise routine for the remaining 3 months
Study NCT01338740 — intervention group
Intervention type: DRUG
Intervention: Adalimumab and Infliximab
Description: Patients with moderately to severely active Crohn's disease with primary non-response or loss of response to Adalimumab switch to Infliximab.
Study NCT03533049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myFAMI
Description: Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge.
Study NCT03533049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myFAMI
Description: Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge.
Study NCT00369265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30mg twice daily
Study NCT00369265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: placebo twice daily
Study NCT03399552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 10mg/kg delivered by IV infusion
Study NCT03399552 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: short course of SBRT after the first two doses of avelumab
Study NCT02765516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant sterols
Description: 2.0g/day of plant sterols incorporated into margarine to be consumed for 28 days
Study NCT02765516 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical margarine without additional plant sterols to be consumed for 28 days
Study NCT03327662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active CTC Assessment
Description: CTC Counts used to guide treatment switch
Study NCT02699749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-931
Description: TAK-931 oral capsules.
Study NCT02982980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy Guidance
Description: Pre and postoperative assessment and orientation, guidelines for lymphedema prevention and self drainage, follow-up for rehabilitation or maintenance of joint amplitude of shoulder movements and functional return.
Study NCT02982980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy Muscle strengthening
Description: The exercises performed were active-free, with the aid of a stick or resistance by elastic bands and dumbbells for flexion, extension, adduction, abduction, external and internal rotation of the shoulder, and elbow flexion and extension, besides activities to enable movements Functional. The mode of execution of the exercises was isotonic, done slowly and within the joint amplitude reached by the patient, using resistance according to the muscular capacity of each patient.
Study NCT03075514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MKD
Description: Modified ketogenic diet
Study NCT03075514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCT
Description: Medium chain triglyceride ketogenic diet
Study NCT03146416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evinacumab
Description: SC or IV administration of Evinacumab
Study NCT03146416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study NCT02172885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: Mesenchymal Stem Cell Infusions
Study NCT01734616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Old Exercise
Study NCT01734616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Old Acute Cocoa
Study NCT01734616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Old 7 Day Cocoa
Study NCT00335595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOXA
Description: XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks
Study NCT00335595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOXA-A
Description: XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.~One cycle every 3 weeks
Study NCT04117516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: Open carpal tunnel release will be performed, in the theatre, with tourniquet, under local anesthesia and sedation, through a short longitudinal volar classical approach of the hand, that allows to visualize the complete division of the ligament.
Study NCT04117516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous surgery
Description: Percutaneous carpal tunnel release will be performed, ambulatory, with a percutaneous scalpel, through a short transverse volar approach, 1-2cm proximal to the wrist, under Wide Awake Local Anesthesia with No Tourniquet.
Study NCT03755778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 1)
Study NCT03755778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 2)
Study NCT03755778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Day 1 and 8 (Part 3)
Study NCT03755778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Subjects will receive itraconazole once daily from Day 5 to Day 18
Study NCT03755778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Subjects will receive rifampin once daily from Day 5 to Day 16
Study NCT03755778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Description: Subjects will receive quinidine once daily from Day 5 to Day 12
Study NCT05022576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Robotic arm assisted PSMA PET/CT guided prostate biopsy
Description: The patients were positioned prone on PET/CT table. The regional PET/CT image of the lower pelvic region were acquired for the procedure. The images were transferred to the ROBIO™ EX workstation. The ARA workstation determined the needle trajectory, depth of the lesion and angulations. The planned trajectory was appraised for its relationship with the vital organs. Strict surgical aseptic approach was followed for the procedure under local anesthesia. An 18G x 20cm coaxial system was manually introduced through the bush and pushed with the help of robotic arm through the gluteal skin entry site to the predetermined depth in the prostate. The real-time placement of the needle was confirmed with low dose CT and the biopsy specimens were retrieved. After the procedure, patient vitals and any difficulty in micturition were observed for two hours in the recovery area. The specimens were sent for histopathological examination.
Study NCT03460249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BP measurement
Description: the BP will be measured in the chair position followed by the table position and also in the reverse sequence
Study NCT05484752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Peripheral Magnetic Stimulation
Description: Repetitive Peripheral Magnetic Stimulation at knee joint 1 session
Study NCT05484752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Conventional exercise and life style modification
Study NCT05484752 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Education
Description: Conventional exercise and life style modification
Study NCT03450122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC
Study NCT00371865 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: 8 group-administered sessions of Cognitive-Behavioral Therapy; includes relaxation, cognitive restructuring, and problem-solving
Study NCT00371865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based therapy
Description: 8 group-administered sessions of Acceptance-based therapy; includes mindfulness, values, and committed action
Study NCT04500782 — intervention group
Intervention type: OTHER
Intervention: Observation at home.
Description: An appointment will be made at home, first one of the parents will be interviewed using the 'Social Functioning' subdomain of the PEDI-NL (Ostensjo, Bjorbaekmo, Brogren Carlberg, \& Vollestad, 2006) to determine the validity of the CFCS-NL and the VSS NL . This section contains some aspects that question the communication skills. The PEDI-NL was chosen as there is no gold standard to investigate functional communication in people with CP. Most standardized test and observational instruments only investigate language comprehension and / or language production and are furthermore developed for normally developing children. On the other hand, a video recording will be made in which the child interacts with a relative and an unknown person (the researcher) so that the CFCS-NL and VSS-score can be determined by the student and the speech therapists of the CP reference center.
Study NCT01383577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single hemorrhoidal ligation
Description: Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each of three sessions of treatment. Final revision is performed 90 days after first session of hemorrhoidal ligation.
Study NCT01383577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triple hemorrhoidal ligation
Description: The three major hemorrhoidal groups are ligated in the first session of ligation. Sham triple hemorrhoidal ligations are performed 30 and 60 days after the first session. Final revision is done 90 days after first ligation session.
Study NCT00254462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Participants will receive atomoxetine for 8 weeks up to a maximum of 1.8 mg/kg/day. Dosed once daily in capsule formulation.
Study NCT00254462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation.
Study NCT00254462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: All children will receive parent training for the duration of the study.
Study NCT00254462 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Parent Training
Description: All children will receive parent training for the duration of the study.
Study NCT02323269 — intervention group
Intervention type: DRUG
Intervention: dimethyl fumarate
Description: administered according to the local product label (i.e., Canadian Product Monograph).
Study NCT00376870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: pioglitazone 30 mg/d
Study NCT00376870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 30 mg/d
Study NCT02528903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHAB5553A
Description: Single intravenous administration, at various doses, depending on the cohort
Study NCT02528903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Single intravenous dose
Study NCT02270242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT02270242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02270242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Study NCT02270242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ticagrelor
Study NCT02324075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change
Description: Non governmental organization delivers communication intervention with facilitating hardware, a waste bin and bucket
Study NCT03319485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Pallidotomy
Description: ExAblate Pallidotomy for Parkinson's Disease
Study NCT03319485 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ExAblate Pallidotomy
Description: ExAblate MRgFUS Sham Procedure
Study NCT01950871 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prostate HistoScanning
Description: In a single visit, subjects will first be imaged with TRUS for the purpose of generating data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo two consecutive biopsy procedures. First, using TRUS, a systematic 10- to 12-core biopsy procedure will be performed. In turn, prostate HS data taken at the beginning of the procedure will be used to determine suspicious areas (displayed as red on an imaging monitor) and used to guide the biopsy procedure. Areas that are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero to a maximum of 6 cores.
Study NCT03010124 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Study NCT00766038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human Growth Hormone
Description: 400 micrograms/day SC for 6 months. Dose adjusted based on serum IGF-1 measurements
Study NCT00766038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection daily
Study NCT00982865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC1936369B
Study NCT02348775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GlyNAC (combination of glycine and n-acetylcysteine)
Description: HIV patients will be studied before and after receiving GlyNAC
Study NCT01973712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Locked Compression Plating
Study NCT01973712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde Intramedullary Nailing (RIMN)
Study NCT02216864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiple Subcision
Description: At the start of the procedure, a straight vitrectomy knife will be inserted subdermally and will be slowly advanced parallel to the dermis. Rapid advancement and retraction of the needle under the scarred area in a lancing motion will be performed to abrade the underside of the dermis followed by side to side sweeping motions attempting to break any fibrous attachments to the deeper tissues.
Study NCT01497639 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interleaving stimulation mode (Medtronic)
Description: Interleaving stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Interleavingr stimulation mode (Medtronic)'
Study NCT01497639 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double monopolar stimulation mode (Medtronic)
Description: Double monopolar stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Double monopolar stimulation mode (Medtronic)'
Study NCT02145286 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT is a high dose and highly conformal radiation dose treatment with the goal of rapid tumor killing and/or ablation of tumors
Study NCT04305522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic 1
Description: Probiotic mixture with maltodextrin as a carrier.
Study NCT04305522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator with maltodextrin as a carrier.
Study NCT04305522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic 2
Description: Probiotic mixture with maltodextrin as a carrier.
Study NCT02458755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
Description: Atorvastatin 40mg or Rosuvastatin 20mg
Study NCT03380260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paranoia Induction
Description: Behavioral procedure involving social exclusion and negative feedback to induce paranoia
Study NCT01199029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04308515
Description: 10 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test(OGTT)
Study NCT01199029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04308515
Description: 10 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test(OGTT)